Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix Keil

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Wiener Klinische Wochenschrift|July 15, 2018
Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectivesPeter Valent, Emir Hadzijusufovic, Thomas Grunt, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Haematologica|April 26, 2015
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trialUlrich Jaeger, Marek Trneny, Helen Melzer, et al.
European Surgery : ACA : Acta Chirurgica Austriaca|December 19, 2018
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expectedSonja Kappel-Latif, Johannes Zacherl, Michael Hejna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
American Journal of Hematology|February 23, 2023
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasmsDaniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
American Journal of Hematology|March 30, 2021
Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasmsKlára Obrová, Silke Grumaz, Marlene Remely, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Wiener Klinische Wochenschrift|July 15, 2018
Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectivesPeter Valent, Emir Hadzijusufovic, Thomas Grunt, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
Haematologica|April 26, 2015
Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trialUlrich Jaeger, Marek Trneny, Helen Melzer, et al.
European Surgery : ACA : Acta Chirurgica Austriaca|December 19, 2018
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expectedSonja Kappel-Latif, Johannes Zacherl, Michael Hejna, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
American Journal of Hematology|August 7, 2023
Cox proportional hazards deep neural network identifies peripheral blood complete remission to be at least equivalent to morphologic complete remission in predicting outcomes of patients treated with azacitidine-A prospective cohort study by the AGMTLisa Pleyer, Marc Vaisband, Manuel Drost, et al.
American Journal of Hematology|February 23, 2023
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasmsDaniel Ivanov, Jelena D Milosevic Feenstra, Irina Sadovnik, et al.
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
International Journal of Molecular Sciences|April 30, 2020
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 PatientsKlaus Geissler, Eva Jäger, Agnes Barna, et al.
American Journal of Hematology|March 30, 2021
Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasmsKlára Obrová, Silke Grumaz, Marlene Remely, et al.
Pageof 9